Cost-effectiveness of managing HIV infection
Abstract
The worldwide spread of HIV infection continues, particularly in economically vulnerable, developing and emerging countries. There is a lack of resources to supply effective prevention measures and apply highly active antiretroviral therapies. In the regions concerned, economical effects of morbidity- and mortality-associated productivity losses in those of a working age remain serious. Thus, the United Nations Program on HIV/AIDS and the World Health Organization have predicted a dramatic decrease of South Africa's and other African states' domestic product in the coming years. Therefore, with the world economical consequences from the HIV pandemic, a large political challenge in the next 10 years will arise.
Details
- Organisation(s)
-
Institute of Insurance Business Administration
- External Organisation(s)
-
Hannover Medical School (MHH)
- Type
- Review article
- Journal
- Expert Review of Pharmacoeconomics and Outcomes Research
- Volume
- 4
- Pages
- 79-88
- No. of pages
- 10
- ISSN
- 1473-7167
- Publication date
- 2004
- Publication status
- Published
- Peer reviewed
- Yes
- ASJC Scopus subject areas
- Health Policy, Pharmacology (medical)
- Sustainable Development Goals
- SDG 3 - Good Health and Well-being
- Electronic version(s)
-
https://doi.org/10.1586/14737167.4.1.79 (Access:
Closed
)
